Topic: ZymoGenetics Inc.
Bristol-Myers Squibb (BMY) decided to buy its hepatitis C drug development partner ZymoGenetics (ZGEN) for $885 million to gain full ownership of the promising PEG-interferon lambda. Bristol-Myers' offer of $9.75 per share in cash represents an 84 percent premium to its closing ...
Bristol-Myers Squibb (NYSE:BMY) may have the unfortunate distinction of being among the most highly-concentrated pharmaceutical companies in the U.S. (For a quick refresher on this, check out Top-Heavy Pharmaceuticals), but management is certainly looking to do something about that. After Monday's close, ...
Bristol-Myers Squibb Co. said Tuesday it will acquire biotechnology partner ZymoGenetics Inc. for $885 million in another move by a major drugmaker to boost its pipeline by snapping up a smaller developer. The New York drugmaker's $9.75-per-share bid represents a 77 percent ...
Bristol-Myers Squibb says it will buy ZymoGenetics for $885M, or $9.75 per share in cashBristol-Myers Squibb Co. says it will acquire biotechnology company ZymoGenetics Inc. for $885 million, or $9.75 per share.The New York drugmaker says its bid is worth $735 million ...
PEG-Interferon lambda is a Novel Type 3 Interferon in Phase Ib trials. ZGEN) today announced a global collaboration for PEG-Interferon lambda, a novel type 3 interferon currently in Phase Ib development for the treatment of Hepatitis C, and its related development program.. ...
ZymoGenetics Announces FDA Approval of Recothrom 20,000-IU Vial Size and Co-Packaging with Spray Kit
ZymoGenetics, Inc. announced today that the United States Food and Drug Administration (FDA) has approved a Prior Approval Supplement application for a 20,000 international unit (IU) vial of Recothrom Thrombin, topical (Recombinant) and also approved co-packaging of the 20,000-IU vial with the ...
ZymoGenetics, Inc. today announced that the United States Food and Drug Administration (FDA) has approved Recothrom Thrombin, topical (Recombinant) for sale. Under a global collaboration, Bayer HealthCare Pharmaceuticals will support the launch of Recothrom in the US for three years. The FDA ...
